Story

BlossomHill Therapeutics Prices Upsized $150 Million IPO at $16 Per Share

ENTHMSVIIDZHZH-TWJAKOHI
Aug 7, 20261 min read
BlossomHill Therapeutics Prices Upsized $150 Million IPO at $16 Per Share
Text size
Background

BlossomHill Therapeutics, Inc., a biopharmaceutical firm developing small molecule cancer treatments, announced it has priced its upsized initial public offering to raise $150.0 million in gross proceeds. The company will offer 9,375,000 shares of common stock at a public price of $16.00 per share, according to a press release dated August 6, 2026.

Offering Details

The offering was increased in size from its initial plans, a signal that may suggest strong investor demand. Shares are expected to begin trading on the Nasdaq Global Select Market on August 7, 2026, under the ticker symbol BLSM. The offering is anticipated to close on August 10, 2026, subject to customary closing conditions.

Key figures from the IPO pricing include:

  • Shares Offered: 9,375,000
  • Price Per Share: $16.00
  • Gross Proceeds: $150.0 million, before deducting underwriting discounts and commissions.
  • Underwriter Option: Underwriters have a 30-day option to purchase up to an additional 1,406,250 shares at the IPO price.

Company Background and Pipeline

Sample IUX Markets – In-articleAd

Based in San Diego, BlossomHill Therapeutics focuses on developing targeted therapies for cancer. The capital raised from the IPO will likely be used to advance its clinical programs.

The company's lead investigational drugs include BH-30643, an EGFR inhibitor for non-small cell lung cancer, and BH-30236, a CLK inhibitor being developed for acute myeloid leukemia and higher-risk myelodysplastic syndrome.

Market Significance

The IPO is being managed by a syndicate of investment banks, with J.P. Morgan, Leerink Partners, and Guggenheim Securities serving as lead book-running managers. LifeSci Capital and H.C. Wainwright & Co. are acting as joint book-running managers. The successful pricing and upsized nature of the offering provide a key data point on investor appetite for clinical-stage biotechnology companies in the current market.

Read next

More on Stocks
Back to latest news

LATEST